Predisposition to prolonged neutropenia after chemotherapy for paediatric acute myeloid leukaemia is associated with better prognosis in the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study.
Takahiro AokiHiroyuki TakahashiShiro TanakaNorio ShibaDaiichiro HasegawaShotaro IwamotoKiminori TeruiHiroshi MoritakeHideki NakayamaAkira ShimadaKatsuyoshi KohHiroaki GotoYoshiyuki KosakaAkiko M SaitoKeizo HoribeAkitoshi KinoshitaAkio TawaTakashi TagaSouichi AdachiDaisuke TomizawaPublished in: British journal of haematology (2020)
The variability in myelosuppression after chemotherapy for acute myeloid leukaemia (AML) can affect its prognosis; however, the underlying mechanism remains controversial. In the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study, we showed that prolonged neutropenia was associated with high overall survival (P = 0·011) and low frequency of relapse (P = 0·042) in patients without granulocyte-colony stimulating factor (G-CSF) who completed the indicated treatment protocol. Our data indicate that predisposition to prolonged neutropenia after chemotherapy is correlated with a better outcome of AML treatment. Our results promote the usage of individualised drug dosing strategies to improve the therapeutic outcome in AML patients.
Keyphrases
- acute myeloid leukemia
- end stage renal disease
- emergency department
- intensive care unit
- chronic kidney disease
- randomized controlled trial
- diffuse large b cell lymphoma
- allogeneic hematopoietic stem cell transplantation
- prognostic factors
- liver failure
- peritoneal dialysis
- radiation therapy
- immune response
- hepatitis b virus
- chemotherapy induced
- machine learning
- artificial intelligence
- respiratory failure
- free survival